s.aureaus

US-based drugmaker Pfizer has commenced the Phase IIb clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery.

The company has enrolled the first patient in the Saphylococcus aureus surgical inpatient vaccine efficacy (STRIVE) trial to study the safety and efficacy of the vaccine to find out if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery.

The vaccine is designed to prevent a wide-range of clinical disease manifestations, caused by S. aureus, by facilitating killing of the bacteria at the early stages of invasive infection by targeting multiple virulence mechanisms.

“To date, there is no licenced vaccine available to prevent invasive S. aureus disease.”

Pfizer vaccine research and development senior vice-president and chief scientific officer Dr Kathrin Jansen said: “To date, there is no licenced vaccine available to prevent invasive S. aureus disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe results from this study, if positive, will bring us closer to a potential preventive measure for this challenging disease that is associated with considerable morbidity and mortality.”

The company plans to enrol around 2,600 subjects in the study, which is expected to complete in 2017.

The primary outcome of the study will evaluate the number of subjects in each treatment group with postoperative S. aureus blood stream infections and deep incisional or organ/space surgical site infections occurring within 90 days after elective posterior instrumented lumbar spinal fusion.

In addition, the secondary outcomes will assess postoperative S. aureus blood stream infections and deep incisional or organ/space surgical site infections occurring within 180 days after surgery, and postoperative S. aureus surgical site infections occurring within 90 and 180 days after elective posterior instrumented lumbar spinal fusion.

February 2014 saw the firm’s S. aureus vaccine receive fast track status from the US Food and Drug Administration (FDA).

Image: The scanning electron micrograph (SEM) shows a strain of Staphylococcus aureus bacteria taken from a vancomycin intermediate resistant culture (VISA). Photo: courtesy of Janice Haney Carr.